BioCentury | Jan 19, 2018
Clinical News

Eiger discontinues ubenimex for PAH

...Eiger BioPharmaceuticals Inc. (NASDAQ:EIGR) discontinued development of ubenimex to treat pulmonary arterial hypertension (PAH). The company...
...aminopeptidase (RNPEP; AP-B) inhibitor to treat lymphedema. Data from the Phase II ULTRA trial of ubenimex...
...BioPharmaceuticals Inc. (NASDAQ:EIGR), Palo Alto, Calif. Nippon Kayaku Co. Ltd. (Tokyo:4272), Tokyo, Japan Product: Bestatin ubenimex...
BioCentury | Jan 16, 2018
Clinical News

Phase II PAH readout sinks Eiger shares

...Eiger BioPharmaceuticals Inc. (NASDAQ:EIGR) lost $7.90 (49%) to $8.10 Tuesday after discontinuing development of ubenimex to...
...aminopeptidase (RNPEP; AP-B) inhibitor to treat lymphedema. Data from the Phase II ULTRA trial of ubenimex...
...as Bestatin in Japan as an adjunct to chemotherapy agents for acute non-lymphocytic leukemia. Jaime De Leon Bestatin ubenimex Eiger...
BioCentury | May 19, 2017
Clinical News

Eiger completes enrollment in Phase II to treat PAH

...with pulmonary arterial hypertension (PAH) in the North American Phase II LIBERTY trial evaluating Bestatin ubenimex...
...of care (SOC). Patients in the double-blind, placebo-controlled trial will receive thrice-daily 150 mg oral Bestatin...
...BioPharmaceuticals Inc. (NASDAQ:EIGR), Palo Alto, Calif. Nippon Kayaku Co. Ltd. (Tokyo:4272), Tokyo, Japan Product: Bestatin ubenimex...
BioCentury | Feb 1, 2017
Clinical News

Bestatin: LIBERTY2 extension study started

...Eiger began the open-label LIBERTY2 extension study of oral Bestatin for ≥24 weeks in about 45...
...develop Bestatin for PAH and inflammatory diseases that involve leukotriene B4 (LTB4) . Nippon markets Bestatin...
...BioPharmaceuticals Inc. (NASDAQ:EIGR), Palo Alto, Calif. Nippon Kayaku Co. Ltd. (Tokyo:4272), Tokyo, Japan Product: Bestatin ubenimex...
BioCentury | Aug 8, 2016
Clinical News

Bestatin ubenimex: Phase II started

...the double-blind, placebo-controlled, U.S. Phase II ULTRA trial to evaluate thrice-daily 150 mg oral Bestatin ubenimex...
...for 24 weeks in about 40 patients. In 2015, Nippon granted Eiger rights to develop Bestatin...
...BioPharmaceuticals Inc. (NASDAQ:EIGR), San Carlos, Calif. Nippon Kayaku Co. Ltd. (Tokyo:4272), Tokyo, Japan Product: Bestatin ubenimex...
BioCentury | Dec 14, 2015
Company News

Nippon Kayaku, Eiger deal

...Nippon granted Eiger rights to develop Bestatin ubenimex for pulmonary arterial hypertension (PAH) and inflammatory diseases...
...pulmonary arterial hypertension (PAH) and inflammatory diseases that involve leukotriene B4 (LTB4) . Nippon markets Bestatin...
BioCentury | Dec 3, 2015
Targets & Mechanisms

The two faces of LTA4H

...II testing for acne. Last month, Eiger Biopharmaceuticals Inc. announced it will begin repurposing Bestatin ubenimex...
...site inhibitor that targets LTA4H and other peptidases, for pulmonary arterial hypertension (PAH) and lymphedema. Bestatin...
BioCentury | Nov 20, 2015
Company News

Eiger reverse-merges with Celladon

...to begin enrollment in Phase II trials of exendin (9-39) to treat hypoglycemia and Bestatin ubenimex...
BioCentury | Feb 12, 2009
Distillery Therapeutics

Indication: Infectious disease

...growth and development within the erythrocyte. X-ray crystallography of PfA-M1 alone and in complex with bestatin...
...Co4 identified features within the protease active site of PfA-M1 that were critical for function. Bestatin...
Items per page:
1 - 9 of 9